ClinicalTrials.gg
RecruitingNCT07361783HELP-PCI-2Updated Jun 17, 2026

Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI-2 Trial

An interventional study of Unfractionated heparin treatment in Primary PCI and ST-elevation Myocardial Infarction (STEMI), sponsored by Chen Jing. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Chen Jing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,294
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 40 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.

Planned enrollment
4th of 97
6,294 · median 320
Started
2026
with 11 others
No phase
51 of 146
21 open now
Primary completion
2029-12
later than 39 of 42 live
Registered
136th of 146
by date

Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 4th largest by planned enrollment of the 97 interventional ones that give a count, is one of 12 that started in 2026, is one of 51 with no phase, reaches primary completion later than 39 of the 42 other live ones, and was the 136th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

40 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in ST Elevation Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

This randomized, multicenter, prospective trial will enroll 6,294 participants in approximately 80 centers. STEMI patients with onset time within 12 hours and scheduled for primary PCI will be randomly assigned to two groups in a 1:1 ratio. Patients meeting the criteria were randomly assigned. It is recommended that loading doses of dual antiplatelet therapy be administered immediately after electrocardiogram diagnosis. The experimental group was required to be given an intravenous injection of 100 U/kg of UFH within 10 minutes after randomization, and this should be completed at least before delivery to the catheter lab. The control group was recommended to be given 100 U/kg of UFH through the arterial sheath, but the actual intraoperative dosage was determined by the interventional cardiologist. No patient is allowed to use low-molecular-weight heparin, bivalirudin, glycoprotein IIb/IIIa inhibitors or other antithrombotic drugs before coronary angiography. The planned enrollment period for this study is 24 months. The scheduled follow-up visits will occur at 30 days (±7 days), 3 months (±14 days), and if conditions permit, at 6 months (±30 days) and 1 year (±30 days) after randomization. The purpose of this study is to evaluate the composite endpoint of all-cause death, recurrent myocardial infarction, urgent coronary revascularization, stent thrombosis, or stroke within 30 days after randomization.

03

Conditions studied

  • Primary PCI
  • ST-elevation Myocardial Infarction (STEMI)

Keywords

  • Heparin
  • Primary Percutaneous Coronary Intervation
  • ST-Elevation Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years old;
  2. STEMI within 12 hours of onset Newly developed adjacent two or more leads with ST segment elevation of ≥1mm (lead V2-V3 elevation of ≥2mm).

    Newly developed left bundle branch block (LBBB). In the right bundle-branch block (RBBB), the ST segment of leads V1-V3 is elevated or Q waves occur.

  3. Primary PCI was planned if the time from first medical contact to balloon dilatation was expected to be less than 120 minutes.

Exclusion criteria

Exclusion Criteria:

  1. Thrombolytic therapy recipients;
  2. Currently taking oral anticoagulant drugs or having been treated with heparin, low molecular weight heparin, suldaparinol sodium, bivalirudin or IIb/IIIa receptor antagonists within 48 hours before randomization;
  3. Patients undergoing cardiopulmonary resuscitation;
  4. Patients with cardiogenic shock;
  5. Combined mechanical complications (rupture of the free wall of the heart, perforation of the ventricular septum, insufficiency or rupture of the papillary muscle leading to severe mitral regurgitation);
  6. History of intracranial parenchymal aneurysm, intracranial arteriovenous malformation, intracranial hemorrhage, ischemic stroke or within the last 6 months, and active hemorrhage within the last 2 weeks;
  7. Major surgery within one month;
  8. Previous history of CABG;
  9. Patients with a history of heparin-induced thrombocytopenia or those known to be allergic to anticoagulant or antiplatelet drugs;
  10. Combined with other serious diseases and less than 12 months;
  11. Pregnant or lactating women;
  12. Currently participating in clinical research on other drugs or devices;
  13. Refuse to sign the form;
  14. The researcher judged that it was not suitable to participate in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
6,294 participants (estimated)

Study arms

  • Experimental
    Administration of Heparin at the first medical contact

    The experimental group was treated with a loading dose of 100U/kg of unfractionated heparin at the first medical contact

    Drug: Unfractionated heparin treatment

  • Active comparator
    Administration of Heparin in the catheterization laboratory

    the control group was treated with a loading dose of 100U/kg of unfractionated heparin in the catheterization laboratory.

    Drug: Unfractionated heparin treatment

Interventions

  • DrugUnfractionated heparin treatment

    An intravenous injection of 100 U/kg of UFH will be given at first medical contact before primary PCI (if assigned to experimental group) or in the catheter lab through the arterial sheath when starting primary PCI (if assigned to control group)

06

What researchers measure

Primary outcomes

  1. The composite endpoint of all-cause death, recurrent myocardial infarction, urgent coronary revascularization, stent thrombosis, or stroke within 30 days after randomization

    The composite endpoint of all-cause death, recurrent myocardial infarction, urgent coronary revascularization, stent thrombosis, or stroke within 30 days after randomization

    Time frame: Within 30 days after randomization.

  2. Primary safety endpoint: Major bleeding (BARC type 3~5) within 30 days

    Major bleeding (BARC type 3\~5)

    Time frame: within 30 days after randomization

Secondary outcomes

  1. Net Clinical Adverse Event

    Composite of all-cause death, recurrent myocardial infarction, urgent coronary revascularization, stent thrombosis, stroke, and BARC type 3-5 bleeding

    Time frame: With 30 days and 90 days after randomization

  2. Individual Clinical Adverse Event

    all-cause death, cardiovascular death, recurrent myocardial infarction, urgent coronary revascularization, stent thrombosis, or stroke

    Time frame: Within 30 days and 90 days after randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 47 months is above that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Jan 23, 2026
StartActual
Jan 25, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Apr 1, 2030
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07361783
Lead sponsor
Chen Jing
Collaborators
Renmin Hospital of Wuhan University, Xianning Central Hospital, Hubei University of Medicine, Yichang Central People's Hospital, Xiangyang Central Hospital, Caidian District People's Hospital, Chibi People's Hospital, Jiangxia First People's Hospital, Anlu Pu'ai Hospital, Jingzhou Central Hospital, The Fifth Hospital of Wuhan, Shiyan People's Hospital, The Third People's Hospital of Hubei Province, China Resources Wugang General Hospital, Wuhan Puren Hospital, Sinopharm Dongfeng General Hospital, Changjiang Shipping General Hospital, Wuhan No.1 Hospital, Wuhan No.3 Hospital, Xishui County People's Hospital, Xiangyang Hospital of Traditional Chinese Medicine, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Jiangling People's Hospital, Wuhan No.6 Hospital, The Central Hospital of Huanggang, Laohekou First Hospital, Wuxue First People's Hospital, Hanyang University, The First People's Hospital of Tianmen, Xianning First People's Hospital, Wuhan Hospital of Traditional Chinese Medicine, Wuhan Central Hospital, The Second Affiliated Hospital of Harbin Medical University, Second Xiangya Hospital of Central South University, Tongcheng People's Hospital of Anhui province, Songzi People's Hospital, Xiantao First People's Hospital, Ezhou Central Hospital, People's Hospital of Jingshan
Responsible party
Chen Jing (MD, PhD, Renmin Hospital of Wuhan University) — Sponsor-investigator
First posted
Jan 23, 2026
Start date
Jan 25, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Jun 17, 2026

Study contacts

Liwei Chen
Contact
renminkjc@163.com
(86)027-88041911 ext. 86346
Jing Chen, PhD
principal investigator · Renmin Hospital of Wuhan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion